Table 1

Patient characteristics and C225 doses

Acc no.	C225 dose (mg/m²; loading/weekly)	Age (yr)/Sex	Primary site	Recurrent site	Previous therapy
1	100/100	630/F	Base of tongue	Dermal	S^a + RT
2	100/100	36/M	Oral tongue	Locoregional	S + RT + gene therapy
3	100/100	63/M	Alveolar ridge	Locoregional	S + RT
4	100/100	72/M	Tonsil	Dermal	S + RT
5	100/100	46/F	Soft palate	Locoregional	S + RT + 5-fluorouracil + cisplatin; IFN-α + 13-cRA
6	500/250	74/M	Base of tongue	Dermal	S + RT; paclitaxel + gemcitabine
7	500/250	50/M	Base of tongue	Dermal	S + RT
8	500/250	55/F	Larynx	Dermal	S + RT; 5-fluorouracil + cisplatin
10	500/250	78/F	Mucosal lip	Locoregional	S + RT
9	400/250	55/M	Hypopharynx	Dermal	S + RT
11	400/250	68/M	Retromolar trigone	Distant	S + bryostatin
12	400/250	39/F	Oral tongue	Locoregional	S + RT; 5-fluorouracil + cisplatin + paclitaxel